NeuroPace announced preliminary one-year results from its clinical study evaluating neuromodulation therapy for generalized ...

NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA ...

"We view the totality of the data in the NAUTILUS study as a meaningful catalyst that adds to the growing body of evidence and momentum in our business,” said Joel Becker, Chief Executive Officer.